Results of a phase II clinical trial on the safety and effectiveness of low dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology. The results of the study suggest that LDN is safe and may have positive effects on the mental quality of life in people with MS; but no effect on a patient’s physical quality of life…